恒瑞医药SHR-1918注射液上市许可申请获受理

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a notice from the National Medical Products Administration regarding the acceptance of its drug listing application for the innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1 - The SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), developed independently by Heng Rui Medicine [1] - The mechanism of SHR-1918 involves inhibiting the activity of ANGPTL3 to lower serum triglycerides (TG) and LDL-C levels [1] - The proposed indication for SHR-1918 is for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia [1]